News & Updates
Filter by Specialty:
Famotidine for mild-to-moderate COVID-19 succeeds in phase II trial
Use of famotidine in the treatment of outpatients with mild-to-moderate COVID-19 is safe and well tolerated, leading to rapid resolution of symptoms and inflammation without reducing anti-SARS-CoV-2 immunity, according to the results of a phase II trial.
Famotidine for mild-to-moderate COVID-19 succeeds in phase II trial
25 Feb 2022Dysglycaemia may increase likelihood of deterioration in non-severe COVID-19 patients
Patients with non-severe coronavirus disease 2019 (COVID-19) who have worse glycaemic status are more likely to deteriorate clinically, but glycaemic status does not adversely impact neutralizing antibody (NAb) responses, researchers from the University of Hong Kong have shown.
Dysglycaemia may increase likelihood of deterioration in non-severe COVID-19 patients
24 Feb 2022Booster dose effective in reducing COVID-19 across ages in adults
The risk of COVID-19 is substantially reduced in adults who receive a third “booster” dose of the BNT162b2 vaccine regardless of their age, according to a study from Israel.
Booster dose effective in reducing COVID-19 across ages in adults
23 Feb 2022Intranasal influenza-based booster induces mucosal immunity against SARS-CoV-2 in animal model
Research from the University of Hong Kong (HKU) demonstrates that intranasal influenza-based booster vaccination following PD1-based receptor-binding domain (RBD) DNA vaccine induces mucosal and systemic immunity for effective prevention of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in both upper and lower respiratory systems of mice.
Intranasal influenza-based booster induces mucosal immunity against SARS-CoV-2 in animal model
23 Feb 2022BNT162b2 and CZ02 neutralizing antibody titres lower against Omicron vs earlier variants
A study by the University of Hong Kong (HKU) has found that immune sera from mRNA-based BNT162b2 and inactivated CZ02 vaccine recipients have substantially reduced neutralizing antibody titres against the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
BNT162b2 and CZ02 neutralizing antibody titres lower against Omicron vs earlier variants
23 Feb 2022Increased risk of herpes zoster hospitalization after COVID-19 vaccination
A self-controlled case series reported by researchers from the University of Hong Kong has identified an increased risk of herpes zoster–related hospitalization associated with mRNA-based BNT162b2 and inactivated CZ02 vaccination against coronavirus disease 2019 (COVID-19).
Increased risk of herpes zoster hospitalization after COVID-19 vaccination
23 Feb 2022Knowing someone with COVID-19 a key predictor of vaccine uptake among HK adolescents
An online survey of over 2,500 Hong Kong adolescents has identified knowing someone diagnosed with coronavirus disease 2019 (COVID-19), having at least one vaccinated parent, and receiving the influenza vaccine in the past year as three top predictors of COVID-19 vaccine acceptance.
Knowing someone with COVID-19 a key predictor of vaccine uptake among HK adolescents
23 Feb 2022Self-reported adverse reactions less likely after inactivated CZ02 vs mRNA-based BNT162b2
A prospective cohort study by the University of Hong Kong comparing the reactogenicity of coronavirus disease 2019 (COVID-19) vaccines reports a lower risk of self-reported adverse reactions following vaccination with inactivated CZ02 compared with mRNA-based BNT162b2.
Self-reported adverse reactions less likely after inactivated CZ02 vs mRNA-based BNT162b2
23 Feb 2022Why do some PCR-negative patients test positive on COVID-19 blood tests?
Serological assays for the coronavirus disease 2019 (COVID-19) sometimes show contradictory findings when compared with nasopharyngeal swab polymerase chain reaction (PCR) tests, according to a recent Singapore study. In particular, even PCR-negative patients with no known exposure could test positive for antibodies.